Sun Pharma leads India’s pharma sector with strong U.S. specialty drugs, steady earnings growth, and a global footprint..Dr. Reddy’s stands out for biosimilars and complex generics, supported by robust R&D and rising U.S. market demand..Cipla remains a defensive pick, driven by respiratory and HIV drugs, strong domestic sales, and global partnerships..Divi’s Laboratories benefits from global API demand, high margins, and supply chain diversification beyond China..Lupin shows turnaround potential with focus on U.S. generics, chronic therapies, and improving profitability..Read More Stories